Advancing our innovative pipeline
to address unmet needs

Pipeline Overview

We are applying our TransCon technology to build a leading, fully integrated biopharmaceutical company with an independent pipeline of long-acting prodrug therapies that address unmet needs. In addition to our current pipeline of three rare disease endocrinology candidates, we have established oncology as our second therapeutic area of focus.

You are about to access www.ascendispharma.us. The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

Go

You are about to access www.ascendispharma.us. The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

Go